Literature DB >> 16081926

International and multicenter comparison of EUCAST and CLSI M27-A2 broth microdilution methods for testing susceptibilities of Candida spp. to fluconazole, itraconazole, posaconazole, and voriconazole.

A Espinel-Ingroff1, F Barchiesi, M Cuenca-Estrella, M A Pfaller, M Rinaldi, J L Rodriguez-Tudela, P E Verweij.   

Abstract

The aim of this study was to compare MICs of fluconazole, itraconazole, posaconazole, and voriconazole obtained by the European Committee on Antibiotic Susceptibility Testing (EUCAST) and CLSI (formerly NCCLS) methods in each of six centers for 15 Candida albicans (5 fluconazole-resistant and 4 susceptible-dose-dependent [S-DD] isolates), 10 C. dubliniensis, 7 C. glabrata (2 fluconazole-resistant isolates), 5 C. guilliermondii (2 fluconazole-resistant isolates), 10 C. krusei, 9 C. lusitaniae, 10 C. parapsilosis, and 5 C. tropicalis (1 fluconazole-resistant isolate) isolates. CLSI MICs were obtained visually at 24 and 48 h and spectrophotometric EUCAST MICs at 24 h. The agreement (within a 3-dilution range) between the methods was species, drug, and incubation time dependent and due to lower EUCAST than CLSI MICs: overall, 94 to 95% with fluconazole and voriconazole and 90 to 91% with posaconazole and itraconazole when EUCAST MICs were compared against 24-h CLSI results. The agreement was lower (85 to 94%) against 48-h CLSI endpoints. The overall interlaboratory reproducibility by each method was > or =92%. When the comparison was based on CLSI breakpoint categorization, the agreement was 68 to 76% for three of the four species that included fluconazole-resistant and S-DD isolates; 9% very major discrepancies (< or =8 microg/ml versus > or =64 microg/ml) were observed among fluconazole-resistant isolates and 50% with voriconazole (< or =1 microg/ml versus > or =4 microg/ml). Similar results were observed with itraconazole for seven of the eight species evaluated (28 to 77% categorical agreement). Posaconazole EUCAST MICs were also substantially lower than CLSI MIC modes (0.008 to 1 microg/ml versus 1 to > or =8 microg/ml) for some of these isolates. Therefore, the CLSI breakpoints should not be used to interpret EUCAST MIC data.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 16081926      PMCID: PMC1233914          DOI: 10.1128/JCM.43.8.3884-3889.2005

Source DB:  PubMed          Journal:  J Clin Microbiol        ISSN: 0095-1137            Impact factor:   5.948


  9 in total

1.  Standardization of antifungal susceptibility variables for a semiautomated methodology.

Authors:  J L Rodríguez-Tudela; M Cuenca-Estrella; T M Díaz-Guerra; E Mellado
Journal:  J Clin Microbiol       Date:  2001-07       Impact factor: 5.948

2.  Comparative evaluation of NCCLS M27-A and EUCAST broth microdilution procedures for antifungal susceptibility testing of candida species.

Authors:  Manuel Cuenca-Estrella; Wendy Lee-Yang; Meral A Ciblak; Beth A Arthington-Skaggs; Emilia Mellado; David W Warnock; Juan L Rodriguez-Tudela
Journal:  Antimicrob Agents Chemother       Date:  2002-11       Impact factor: 5.191

3.  Influence of incubation time, inoculum size, and glucose concentrations on spectrophotometric endpoint determinations for amphotericin B, fluconazole, and itraconazole.

Authors:  M H Nguyen; C Y Yu
Journal:  J Clin Microbiol       Date:  1999-01       Impact factor: 5.948

4.  Influence of glucose supplementation and inoculum size on growth kinetics and antifungal susceptibility testing of Candida spp.

Authors:  M Cuenca-Estrella; T M Díaz-Guerra; E Mellado; J L Rodríguez-Tudela
Journal:  J Clin Microbiol       Date:  2001-02       Impact factor: 5.948

5.  Multicenter evaluation of the reproducibility of the proposed antifungal susceptibility testing method for fermentative yeasts of the Antifungal Susceptibility Testing Subcommittee of the European Committee on Antimicrobial Susceptibility Testing (AFST-EUCAST).

Authors:  M Cuenca-Estrella; C B Moore; F Barchiesi; J Bille; E Chryssanthou; D W Denning; J P Donnelly; F Dromer; B Dupont; J H Rex; M D Richardson; B Sancak; P E Verweij; J L Rodríguez-Tudela
Journal:  Clin Microbiol Infect       Date:  2003-06       Impact factor: 8.067

6.  Correlation of in-vitro susceptibility test results with clinical response: a study of azole therapy in AIDS patients.

Authors:  J L Rodríguez-Tudela; J V Martínez-Suárez; F Dronda; F Laguna; F Chaves; E Valencia
Journal:  J Antimicrob Chemother       Date:  1995-06       Impact factor: 5.790

7.  Comparison of two alternative microdilution procedures with the National Committee for Clinical Laboratory Standards reference macrodilution method M27-P for in vitro testing of fluconazole-resistant and -susceptible isolates of Candida albicans.

Authors:  A Espinel-Ingroff; J L Rodríguez-Tudela; J V Martínez-Suárez
Journal:  J Clin Microbiol       Date:  1995-12       Impact factor: 5.948

8.  Improved method of determining the susceptibility of Candida albicans to fluconazole.

Authors:  A M Polanco; J L Rodriguez-Tudela; F Baquero; A Sanchez-Sousa; J V Martinez-Suarez
Journal:  J Antimicrob Chemother       Date:  1995-01       Impact factor: 5.790

9.  Comparison of the Antifungal Susceptibility Testing Subcommittee of the European Committee on Antibiotic Susceptibility Testing proposed standard and the E-test with the NCCLS broth microdilution method for voriconazole and caspofungin susceptibility testing of yeast species.

Authors:  Erja Chryssanthou; Manuel Cuenca-Estrella
Journal:  J Clin Microbiol       Date:  2002-10       Impact factor: 5.948

  9 in total
  39 in total

Review 1.  Progress in antifungal susceptibility testing of Candida spp. by use of Clinical and Laboratory Standards Institute broth microdilution methods, 2010 to 2012.

Authors:  M A Pfaller; D J Diekema
Journal:  J Clin Microbiol       Date:  2012-06-27       Impact factor: 5.948

2.  Comparison of the broth microdilution methods of the European Committee on Antimicrobial Susceptibility Testing and the Clinical and Laboratory Standards Institute for testing itraconazole, posaconazole, and voriconazole against Aspergillus isolates.

Authors:  M Pfaller; L Boyken; R Hollis; J Kroeger; S Messer; S Tendolkar; D Diekema
Journal:  J Clin Microbiol       Date:  2011-01-05       Impact factor: 5.948

3.  Multicenter comparison of the VITEK 2 antifungal susceptibility test with the CLSI broth microdilution reference method for testing amphotericin B, flucytosine, and voriconazole against Candida spp.

Authors:  M A Pfaller; D J Diekema; G W Procop; M G Rinaldi
Journal:  J Clin Microbiol       Date:  2007-10-03       Impact factor: 5.948

4.  Molecular analysis and susceptibility profiling of Candida albicans isolates from immunocompromised patients in South India.

Authors:  C P Girish Kumar; Ahmed Medhat Hanafy; Masakazu Katsu; Yuzuru Mikami; Thangam Menon
Journal:  Mycopathologia       Date:  2006-03       Impact factor: 2.574

5.  In Vitro Susceptibility Testing in Fungi: What is its Role in Clinical Practice?

Authors:  Susanne Perkhofer; Cornelia Mrazek; Lukas Hartl; Cornelia Lass-Flörl
Journal:  Curr Infect Dis Rep       Date:  2010-11       Impact factor: 3.725

6.  Validation of 24-hour posaconazole and voriconazole MIC readings versus the CLSI 48-hour broth microdilution reference method: application of epidemiological cutoff values to results from a global Candida antifungal surveillance program.

Authors:  M A Pfaller; L B Boyken; R J Hollis; J Kroeger; S A Messer; S Tendolkar; D J Diekema
Journal:  J Clin Microbiol       Date:  2011-02-02       Impact factor: 5.948

7.  Comparison of the Vitek 2 antifungal susceptibility system with the clinical and laboratory standards institute (CLSI) and European Committee on Antimicrobial Susceptibility Testing (EUCAST) Broth Microdilution Reference Methods and with the Sensititre YeastOne and Etest techniques for in vitro detection of antifungal resistance in yeast isolates.

Authors:  Manuel Cuenca-Estrella; Alicia Gomez-Lopez; Ana Alastruey-Izquierdo; Leticia Bernal-Martinez; Isabel Cuesta; Maria J Buitrago; Juan L Rodriguez-Tudela
Journal:  J Clin Microbiol       Date:  2010-03-10       Impact factor: 5.948

8.  Evaluation by data mining techniques of fluconazole breakpoints established by the Clinical and Laboratory Standards Institute (CLSI) and comparison with those of the European Committee on Antimicrobial Susceptibility Testing (EUCAST).

Authors:  Isabel Cuesta; Concha Bielza; Manuel Cuenca-Estrella; Pedro Larrañaga; Juan L Rodríguez-Tudela
Journal:  Antimicrob Agents Chemother       Date:  2010-02-01       Impact factor: 5.191

9.  Comparison of the broth microdilution (BMD) method of the European Committee on Antimicrobial Susceptibility Testing with the 24-hour CLSI BMD method for testing susceptibility of Candida species to fluconazole, posaconazole, and voriconazole by use of epidemiological cutoff values.

Authors:  M A Pfaller; A Espinel-Ingroff; L Boyken; R J Hollis; J Kroeger; S A Messer; S Tendolkar; D J Diekema
Journal:  J Clin Microbiol       Date:  2011-01-12       Impact factor: 5.948

10.  Validation of 24-hour fluconazole MIC readings versus the CLSI 48-hour broth microdilution reference method: results from a global Candida antifungal surveillance program.

Authors:  M A Pfaller; L B Boyken; R J Hollis; J Kroeger; S A Messer; S Tendolkar; D J Diekema
Journal:  J Clin Microbiol       Date:  2008-09-10       Impact factor: 5.948

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.